A division of Canna I Heal U, powered by Spa D'Ambience. As certified Essential Services providers, we consult in person or telephonically with our clients and courier products to you. We are the A team.

Big Pharma CEO: ‘We’re in Business of Shareholder Profit, Not Helping The Sick’

September 28, 2019 2 min read

Last July, Turing Pharmaceuticals’ CEO Martin Shkreli became a lightning rod for growing outrage over soaring prescription drug prices after he raised the price of a newly-acquired drug from $13.50 to $750. But Shkreli, who earned the title ‘the most hated man in America,’ is not the only one acquiring drugs currently on the market to raise their price and, in turn, rapidly drive up their stock price.

  1. Michael Pearson, the CEO of Valeant Pharmaceuticals has enraged the internet after saying in a recent interviewwith MSNBC that “his company’s responsibility is to its shareholders, not the customers who rely on his drugs to live.”

“My primary responsibility is to Valeant shareholders. We can do anything we want to do. We will continue to make acquisitions, we will continue to move forward,” Pearson said.

He added: “If products are sort of mispriced and there’s an opportunity, we will act appropriately in terms of doing what I assume our shareholders would like us to do.”

Already this year, according to several media outlets, Valeant has increased the price of 56 of the drugs in its portfolio an average of 66 percent, highlighted by their recent acquisition, Zegerid, which they promptly raised 550 percent. Not only does this have the unfortunate side effect of placing the price of life-saving drugs out of reach for even moderately-insured people, but it has now begun to call into question the sustainability of this rapidly-spreading business model.

Valeant has acquired more than 100 drugs and seen their stock price rise more than 1,000 percent since Pearson was named CEO in 2008. Pearson started working with Valeant Pharmaceuticals as an outside consultant in 2007, took over as CEO the next year.

Both Hillary Clinton and Bernie Sanders’ stance against the practice has placed big pharma under tremendous scrutiny.

The House Committee on Oversight and Government Reform is planning to issue a subpoena for information on recent price increases from both Pearson and Shkreli.

Brenda Hutchinson
Brenda Hutchinson


Leave a comment

Comments will be approved before showing up.


Also in News

Only one in 10 medical treatments are backed by high-quality evidence
Only one in 10 medical treatments are backed by high-quality evidence

September 22, 2020 4 min read

A guide to FECO
A guide to FECO

September 20, 2020 3 min read

It is also important to know of which plant based oil is the sellers FECO blended with as you would want the best absorption rate by the body.
Testimonial - Stroke
Testimonial - Stroke

September 19, 2020 1 min read

She can now open her hand completely and has movement again!

Subscribe Today!